WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Miwako, Masuko, Masayoshi, Kurasaki, Tohri, Kitajima, Toshiki, Takenouchi, Shoko, Saitoh, Anri, Watanabe, Norihiro, Furukawa, Tatsuo, Toba, Ken, Fuse, Ichiro, Aizawa, Yoshifusa, Kawakami, Manabu, Oka, Yoshihiro, Sugiyama, Haruo, Takahashi, Masuhiro
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2010
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860640/
https://www.ncbi.nlm.nih.gov/pubmed/20428337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860640/
https://www.ncbi.nlm.nih.gov/pubmed/20428337

Ejemplares similares